Precision treatment in ACS – role of assessing fibrinolysis

Ying X. Gue; Young-Hoon Jeong; Mohamed Farag; Nikolaos Spinthakis; Diana Gorog

doi:10.3390/jcm10050929

Precision treatment in ACS – role of assessing fibrinolysis

Ying X. Gue, Young-Hoon Jeong, Mohamed Farag, Nikolaos Spinthakis, Diana Gorog

Research output: Contribution to journal › Article › peer-review

13 Downloads (Pure)

Abstract

Despite advancements in pharmacotherapy and interventional strategies, patients with acute coronary syndrome (ACS) remain at risk of recurrent thrombotic events. In addition to an enhanced tendency to thrombus formation, impairment in the ability to naturally dissolve or lyse a developing thrombus, namely impaired endogenous fibrinolysis, is responsible for a major part of this residual risk regardless of optimal antiplatelet medication. Global assessment of endogenous fibrinolysis, including a point-of-care assay, can identify patients with ACS at persistent high cardiovascular risk and might play an important role in allowing the personalisation of potent antithrombotic therapy to enhance fibrinolytic status, providing precision treatment of ACS to improve long-term outcome.

Original language	English
Article number	929
Number of pages	8
Journal	Journal of Clinical Medicine (JCM)
Volume	10
Issue number	5
DOIs	https://doi.org/10.3390/jcm10050929
Publication status	Published - 1 Mar 2021

Access to Document

10.3390/jcm10050929Licence: CC BY

final-version
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Final published version, 520 KBLicence: CC BY

Cite this

@article{9099e8a433f247fe9f84d5c02a2bbac0,

title = "Precision treatment in ACS – role of assessing fibrinolysis",

abstract = "Despite advancements in pharmacotherapy and interventional strategies, patients with acute coronary syndrome (ACS) remain at risk of recurrent thrombotic events. In addition to an enhanced tendency to thrombus formation, impairment in the ability to naturally dissolve or lyse a developing thrombus, namely impaired endogenous fibrinolysis, is responsible for a major part of this residual risk regardless of optimal antiplatelet medication. Global assessment of endogenous fibrinolysis, including a point-of-care assay, can identify patients with ACS at persistent high cardiovascular risk and might play an important role in allowing the personalisation of potent antithrombotic therapy to enhance fibrinolytic status, providing precision treatment of ACS to improve long-term outcome.",

author = "Gue, {Ying X.} and Young-Hoon Jeong and Mohamed Farag and Nikolaos Spinthakis and Diana Gorog",

note = "{\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).",

year = "2021",

month = mar,

day = "1",

doi = "10.3390/jcm10050929",

language = "English",

volume = "10",

journal = "Journal of Clinical Medicine (JCM)",

issn = "2077-0383",

publisher = "MDPI Multidisciplinary Digital Publishing Institute",

number = "5",

}

TY - JOUR

T1 - Precision treatment in ACS – role of assessing fibrinolysis

AU - Gue, Ying X.

AU - Jeong, Young-Hoon

AU - Farag, Mohamed

AU - Spinthakis, Nikolaos

AU - Gorog, Diana

N1 - © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PY - 2021/3/1

Y1 - 2021/3/1

N2 - Despite advancements in pharmacotherapy and interventional strategies, patients with acute coronary syndrome (ACS) remain at risk of recurrent thrombotic events. In addition to an enhanced tendency to thrombus formation, impairment in the ability to naturally dissolve or lyse a developing thrombus, namely impaired endogenous fibrinolysis, is responsible for a major part of this residual risk regardless of optimal antiplatelet medication. Global assessment of endogenous fibrinolysis, including a point-of-care assay, can identify patients with ACS at persistent high cardiovascular risk and might play an important role in allowing the personalisation of potent antithrombotic therapy to enhance fibrinolytic status, providing precision treatment of ACS to improve long-term outcome.

AB - Despite advancements in pharmacotherapy and interventional strategies, patients with acute coronary syndrome (ACS) remain at risk of recurrent thrombotic events. In addition to an enhanced tendency to thrombus formation, impairment in the ability to naturally dissolve or lyse a developing thrombus, namely impaired endogenous fibrinolysis, is responsible for a major part of this residual risk regardless of optimal antiplatelet medication. Global assessment of endogenous fibrinolysis, including a point-of-care assay, can identify patients with ACS at persistent high cardiovascular risk and might play an important role in allowing the personalisation of potent antithrombotic therapy to enhance fibrinolytic status, providing precision treatment of ACS to improve long-term outcome.

U2 - 10.3390/jcm10050929

DO - 10.3390/jcm10050929

M3 - Article

SN - 2077-0383

VL - 10

JO - Journal of Clinical Medicine (JCM)

JF - Journal of Clinical Medicine (JCM)

IS - 5

M1 - 929

ER -

Precision treatment in ACS – role of assessing fibrinolysis

Abstract

Access to Document

Fingerprint

Cite this